MA54328A - Hétéromultimères de récepteur de type i et de type ii de la superfamille de tgf-bêta et leurs utilisations - Google Patents

Hétéromultimères de récepteur de type i et de type ii de la superfamille de tgf-bêta et leurs utilisations

Info

Publication number
MA54328A
MA54328A MA054328A MA54328A MA54328A MA 54328 A MA54328 A MA 54328A MA 054328 A MA054328 A MA 054328A MA 54328 A MA54328 A MA 54328A MA 54328 A MA54328 A MA 54328A
Authority
MA
Morocco
Prior art keywords
type
tgf
beta superfamily
receptor heteromultimers
heteromultimers
Prior art date
Application number
MA054328A
Other languages
English (en)
Inventor
Roselyne Castonguay
Asya Grinberg
Ravindra Kumar
Robert Scott Pearsall
Dianne S Sako
Original Assignee
Acceleron Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acceleron Pharma Inc filed Critical Acceleron Pharma Inc
Publication of MA54328A publication Critical patent/MA54328A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/1103—Receptor protein serine/threonine kinase (2.7.11.30)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
MA054328A 2015-04-06 2016-04-06 Hétéromultimères de récepteur de type i et de type ii de la superfamille de tgf-bêta et leurs utilisations MA54328A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562143579P 2015-04-06 2015-04-06

Publications (1)

Publication Number Publication Date
MA54328A true MA54328A (fr) 2021-10-06

Family

ID=57072866

Family Applications (4)

Application Number Title Priority Date Filing Date
MA053400A MA53400A (fr) 2015-04-06 2016-04-06 Hétéromultimères alk7: actriib et leurs utilisations
MA041916A MA41916A (fr) 2015-04-06 2016-04-06 Hétéromultimères de récepteur de type i et de type ii de la superfamille de tgf-bêta et leurs utilisations
MA41920A MA41920B1 (fr) 2015-04-06 2016-04-06 Protéines de fusion de récepteur type i et type ii à bras unique et leurs utilisations
MA054328A MA54328A (fr) 2015-04-06 2016-04-06 Hétéromultimères de récepteur de type i et de type ii de la superfamille de tgf-bêta et leurs utilisations

Family Applications Before (3)

Application Number Title Priority Date Filing Date
MA053400A MA53400A (fr) 2015-04-06 2016-04-06 Hétéromultimères alk7: actriib et leurs utilisations
MA041916A MA41916A (fr) 2015-04-06 2016-04-06 Hétéromultimères de récepteur de type i et de type ii de la superfamille de tgf-bêta et leurs utilisations
MA41920A MA41920B1 (fr) 2015-04-06 2016-04-06 Protéines de fusion de récepteur type i et type ii à bras unique et leurs utilisations

Country Status (15)

Country Link
US (7) US10227392B2 (fr)
EP (4) EP3280728B1 (fr)
JP (3) JP7055636B2 (fr)
KR (2) KR20180002661A (fr)
CN (4) CN107709358A (fr)
AU (4) AU2016244750B2 (fr)
BR (1) BR112017021510A2 (fr)
CA (2) CA2981737A1 (fr)
DK (1) DK3280728T3 (fr)
EA (2) EA037293B1 (fr)
ES (1) ES2863564T3 (fr)
HK (4) HK1248735A1 (fr)
MA (4) MA53400A (fr)
MX (1) MX2017012846A (fr)
WO (2) WO2016164089A2 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016528295A (ja) 2013-08-22 2016-09-15 アクセルロン ファーマ， インコーポレイテッド Ｔｇｆ−ベータ受容体ｉｉ型変異体およびその使用
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
RS61728B1 (sr) 2015-04-06 2021-05-31 Acceleron Pharma Inc Jednograni fuzioni receptorski proteini tipa i i tipa ii i njihove upotrebe
WO2016164089A2 (fr) 2015-04-06 2016-10-13 Acceleron Pharma Inc. Hétéromultimères de récepteur de type i et de type ii de la superfamille de tgf-bêta et leurs utilisations
MA41919A (fr) 2015-04-06 2018-02-13 Acceleron Pharma Inc Hétéromultimères alk4:actriib et leurs utilisations
CA2983440C (fr) 2015-04-22 2024-03-12 Alivegen Usa Inc. Nouvelles proteines hybrides piegeant le ligand actriib pour le traitement de maladies amyotrophiques
US9884900B2 (en) 2015-08-04 2018-02-06 Acceleron Pharma Inc. Methods for treating Janus kinase-associated disorders by administering soluble transforming growth factor beta type II receptor
CN105254764A (zh) * 2015-08-27 2016-01-20 上海康岱生物医药技术有限公司 ACVR1-Fc融合蛋白及其制法和用途
US20170306027A1 (en) 2016-04-06 2017-10-26 Acceleron Pharma Inc. Alk7 antagonists and uses thereof
DK3496739T3 (da) 2016-07-15 2021-05-10 Acceleron Pharma Inc Sammensætninger omfattende actriia-polypeptider til brug i behandlingen af pulmonal hypertension
KR102595559B1 (ko) 2016-10-05 2023-10-30 악셀레론 파마 인코포레이티드 변이체 actriib 단백질 및 이의 용도
US10934532B2 (en) 2016-10-05 2021-03-02 Acceleron Pharma Inc. ALK4.ActRIIB heteromultimers
CN110198743B (zh) * 2016-10-05 2023-07-18 艾科赛扬制药股份有限公司 用于治疗肾脏疾病的组合物和方法
JP7097354B2 (ja) * 2016-10-05 2022-07-07 アクセルロン ファーマ インコーポレイテッド Ｔｇｆ－ベータスーパーファミリーｉ型およびｉｉ型受容体ヘテロ多量体ならびにその使用
KR20240046620A (ko) * 2016-11-17 2024-04-09 2세븐티 바이오, 인코포레이티드 TGFβ 신호 컨버터
CA3051696A1 (fr) * 2017-02-01 2018-08-09 Acceleron Pharma Inc. Antagonistes de tgf.beta et actrii destines a augmenter l'activite immunitaire
SI3628049T1 (sl) 2017-05-04 2023-10-30 Acceleron Pharma Inc. Fuzijske beljakovine receptorja TGF-beta tipa II in njihova uporaba
EP3424957A1 (fr) * 2017-07-03 2019-01-09 advanceCOR GmbH Protéine de fusion
MX2020004561A (es) * 2017-11-02 2020-08-13 Bayer Ag Anticuerpos biespecificos que se unen a alk-1 y bmpr-2.
JP2021512919A (ja) * 2018-02-09 2021-05-20 アクセルロン ファーマ インコーポレイテッド 異所性骨化を処置するための方法
MX2020009272A (es) 2018-03-06 2021-01-08 Univ Pennsylvania Receptores de antígeno quimérico del antígeno de membrana específico de próstata y métodos de uso de los mismos.
US20220372107A1 (en) * 2018-05-03 2022-11-24 Acceleron Pharma Inc. MULTISPECIFIC BINDERS OF TGFBeta-SUPERFAMILY LIGANDS AND USES THEREOF
AU2019262143A1 (en) * 2018-05-03 2020-11-26 Acceleron Pharma Inc. Novel binders of TGFβ-superfamily ligands and uses thereof
CA3098679A1 (fr) * 2018-05-09 2019-11-14 Keros Therapeutics, Inc. Variants du recepteur de l'activine de type iia et leurs procedes d'utilisation
EP3797120A1 (fr) 2018-05-21 2021-03-31 Compass Therapeutics LLC Compositions et procédés pour améliorer la destruction de cellules cibles par des lymphocytes nk
WO2019226658A1 (fr) 2018-05-21 2019-11-28 Compass Therapeutics Llc Compositions multispécifiques de liaison à l'antigène et procédés d'utilisation
WO2019241625A1 (fr) * 2018-06-15 2019-12-19 Acceleron Pharma Inc. Protéines de fusion bi- et tri-fonctionnelles et utilisations associées
CN112625137B (zh) * 2019-10-08 2021-10-08 北京东方百泰生物科技股份有限公司 一种人白细胞介素10-Fc融合蛋白及其医药用途
AU2021236249A1 (en) * 2020-03-13 2022-10-06 Acceleron Pharma Inc. Single-arm ActRIIA and ActRIIB heteromultimers and methods for treating renal diseases or conditions
KR102587871B1 (ko) * 2020-06-19 2023-10-12 숙명여자대학교산학협력단 Bmpr2 유전자 기능획득 돌연변이체를 포함하는 돌연변이 복합체 및 이의 용도
EP4240388A1 (fr) * 2020-11-04 2023-09-13 HAN, Hq Nouveaux antagonistes multispécifiques bifonctionnels capables d'inhiber de multiples ligands de la famille du tgf-bêta et utilisations correspondantes

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0105014B1 (fr) 1982-09-24 1992-05-20 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Rétablissement de tissu chez les animaux
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
WO1990005144A1 (fr) 1988-11-11 1990-05-17 Medical Research Council Ligands a domaine unique, recepteurs comprenant lesdits ligands, procedes pour leur production, et emploi desdits ligands et recepteurs
US5198346A (en) 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5567588A (en) 1990-06-11 1996-10-22 University Research Corporation Systematic evolution of ligands by exponential enrichment: Solution SELEX
US5763177A (en) 1990-06-11 1998-06-09 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US5580737A (en) 1990-06-11 1996-12-03 Nexstar Pharmaceuticals, Inc. High-affinity nucleic acid ligands that discriminate between theophylline and caffeine
EP1493825A3 (fr) 1990-06-11 2005-02-09 Gilead Sciences, Inc. Procédé pour la production de ligands constitués par des acides nucléiques
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5707796A (en) 1990-06-11 1998-01-13 Nexstar Pharmaceuticals, Inc. Method for selecting nucleic acids on the basis of structure
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1992009690A2 (fr) 1990-12-03 1992-06-11 Genentech, Inc. Methode d'enrichissement pour des variantes de l'hormone de croissance avec des proprietes de liaison modifiees
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
US20050186593A1 (en) * 1991-05-10 2005-08-25 The Salk Institute For Biological Studies Cloning and recombinant production of CRF receptor(s)
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (fr) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions induisant la destruction de cellules infectees par l'hiv
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
DE69333807T2 (de) 1992-02-06 2006-02-02 Chiron Corp., Emeryville Marker für krebs und biosynthetisches bindeprotein dafür
US7592428B1 (en) 1992-11-17 2009-09-22 Ludwig Institute For Cancer Research Antibodies which bind specifically to activin receptor like kinases
EP0677104B1 (fr) 1992-11-17 2003-03-19 Ludwig Institute For Cancer Research Kinases du type recepteurs activine, proteines possedant des domaines de kinase de serine/threonine et leur utilisation
US5677196A (en) 1993-05-18 1997-10-14 University Of Utah Research Foundation Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays
US5525490A (en) 1994-03-29 1996-06-11 Onyx Pharmaceuticals, Inc. Reverse two-hybrid method
US5614609A (en) 1994-10-20 1997-03-25 Carlos F. Ibanez Serine threonine kinase receptor
US5814565A (en) 1995-02-23 1998-09-29 University Of Utah Research Foundation Integrated optic waveguide immunosensor
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
AU716893B2 (en) 1995-04-11 2000-03-09 General Hospital Corporation, The Reverse two-hybrid systems
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6699843B2 (en) 1995-06-07 2004-03-02 Gilead Sciences, Inc. Method for treatment of tumors using nucleic acid ligands to PDGF
JPH10303327A (ja) 1997-04-23 1998-11-13 Yamaichi Electron Co Ltd 半導体チップの接点変換構造と該接点変換構造を有する半導体チップの製造法
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6011577A (en) 1997-06-30 2000-01-04 Polaroid Corporation Modular optical print head assembly
JP2001513982A (ja) 1997-08-29 2001-09-11 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド フォリスタチン−３
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
WO1999029888A1 (fr) 1997-12-05 1999-06-17 The Scripps Research Institute Humanisation d'anticorps murins
US6335155B1 (en) 1998-06-26 2002-01-01 Sunesis Pharmaceuticals, Inc. Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
EP1141708A1 (fr) 1998-12-28 2001-10-10 Sunesis Pharmaceuticals Inc. Identification de ligands de type petites molecules organiques, destines a former des liaisons
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
AU772694B2 (en) 1999-01-21 2004-05-06 Metamorphix International, Inc. Growth differentiation factor inhibitors and uses therefor
DE60042021D1 (de) 1999-07-29 2009-05-28 Gilead Sciences Inc Nukleinsäureliganden für den hepatozytischen wachstumsfaktor/dispersionsfaktor (hgf/sf) und seines c-met rezeptors
AU784983B2 (en) 1999-12-15 2006-08-17 Genentech Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
BR0110610A (pt) 2000-04-11 2003-04-29 Genentech Inc Anticorpos isolados, imunoconjugados, cadeias de polipeptìdeos, ácido nucléico isolado, vetor, célula hospedeira, processo de produção de anticorpo ou cadeia de polipeptìdeos, método de tratamento de disfunções em mamìferos, método de indução da apoptose de uma célula cancerosa, método para matar uma célula b, método para matar uma célula que expresse um receptor de erbb e usos dos anticorpos isolados
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
AU2002239422B2 (en) 2000-11-30 2006-12-07 E. R. Squibb & Sons, L.L.C. Transgenic transchromosomal rodents for making human antibodies
AU2003239966B9 (en) 2002-06-03 2010-08-26 Genentech, Inc. Synthetic antibody phage libraries
US20040223966A1 (en) 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
CA2510003A1 (fr) 2003-01-16 2004-08-05 Genentech, Inc. Banques de phages anticorps synthetiques
DE602004022315D1 (de) 2003-09-15 2009-09-10 Res Dev Foundation Cripto-antagonismus von activin und tgf-b signalisierung
US20070135336A1 (en) 2003-09-15 2007-06-14 De Kretser David Follistatin isoforms and uses thereof
US7456149B2 (en) 2004-03-02 2008-11-25 Acceleron Pharma, Inc. ALK7 and myostatin inhibitors and uses thereof
EP1740615B1 (fr) 2004-03-31 2014-11-05 Genentech, Inc. Anticorps anti-tgf-beta humanises
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
EP2360186B1 (fr) 2004-04-13 2017-08-30 F. Hoffmann-La Roche AG Anticorps dirigés contre la sélectine P
US7833971B2 (en) 2006-12-08 2010-11-16 Acceleron Pharma Inc. Uses of cerberus, coco and derivatives thereof
EP3059245B1 (fr) 2004-07-23 2018-11-07 Acceleron Pharma Inc. Anticorps antagonistes du récepteur actrii
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
PL1791565T3 (pl) 2004-09-23 2016-10-31 Modyfikowane cysteiną przeciwciała i koniugaty
EP1957531B1 (fr) 2005-11-07 2016-04-13 Genentech, Inc. Polypeptides de liaison comprenant des sequences diversifiees et des sequences consensus hypervariables vh/vl
CN101370511B (zh) * 2005-11-23 2015-07-01 阿塞勒隆制药公司 Activin-ActRIIa拮抗剂及其促进骨骼生长的应用
PL1973559T3 (pl) 2005-11-23 2013-06-28 Acceleron Pharma Inc Antagoniści aktywiny-ActRIIa i zastosowanie do pobudzania wzrostu kości
WO2007064919A2 (fr) 2005-12-02 2007-06-07 Genentech, Inc. Polypeptides de liaison avec des sequences de diversite limitees
JP2009536527A (ja) 2006-05-09 2009-10-15 ジェネンテック・インコーポレーテッド 最適化されたスキャフォールドを備えた結合ポリペプチド
EP2035456A1 (fr) 2006-06-22 2009-03-18 Novo Nordisk A/S Production d'anticorps bispécifiques
WO2008030367A2 (fr) 2006-09-01 2008-03-13 The General Hospital Corporation Inhibiteurs sélectifs de la myostatine
CN101652387A (zh) * 2006-11-02 2010-02-17 阿塞勒隆制药公司 Alk1受体和配体拮抗剂及其用途
EA035911B1 (ru) * 2006-12-18 2020-08-31 Акселерон Фарма Инк. Применение полипептида, который ингибирует опосредованный активином сигнальный путь, в качестве лекарственного средства
TWI548647B (zh) 2007-02-02 2016-09-11 艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
TWI573802B (zh) 2007-03-06 2017-03-11 安美基公司 變異之活動素受體多肽及其用途
CA2681177C (fr) 2007-03-19 2019-08-20 National Research Council Of Canada Antagonistes de ligands et leurs utilisations
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
JP6157046B2 (ja) 2008-01-07 2017-07-05 アムジェン インコーポレイテッド 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法
KR20190037355A (ko) * 2008-05-02 2019-04-05 악셀레론 파마 인코포레이티드 혈관신생 및 혈관주위세포 적용범위의 조정을 위한 ａｌｋ１ 길항제 기재의 방법 및 조성물
TWI617316B (zh) 2008-08-14 2018-03-11 艾瑟勒朗法瑪公司 使用ｇｄｆ阱以增加紅血球水平
EP2326670A4 (fr) 2008-09-17 2014-04-16 Nat Res Council Canada Agents de liaison hétéro-multivalents pour des membres de la superfamille des tgf-
KR101778134B1 (ko) 2008-11-26 2017-09-13 암젠 인크 액티빈 ｉｉｂ 수용체 폴리펩타이드의 변이체 및 이의 용도
WO2010083034A1 (fr) 2009-01-13 2010-07-22 Acceleron Pharma Inc. Procédés permettant d'augmenter l'adiponectine
KR20170134788A (ko) 2009-03-30 2017-12-06 악셀레론 파마 인코포레이티드 Ｂｍｐ-ａｌｋ3 길항제 및 골 성장을 촉진시키는 사용되는 이의 용도
MX351286B (es) 2009-06-12 2017-10-09 Acceleron Pharma Inc Proteinas de fusion actriib-fc truncadas.
WO2011034605A2 (fr) 2009-09-16 2011-03-24 Genentech, Inc. Complexes protéiques contenant une super-hélice et/ou une attache et leurs utilisations
FR2951408B1 (fr) 2009-10-15 2012-01-13 Renault Sa Cadre moteur pour moteur electrique de vehicule automobile
TWI426920B (zh) * 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體
WO2012027065A2 (fr) * 2010-08-27 2012-03-01 Celgene Corporation Polythérapie pour traiter des maladies
CN102850458B (zh) 2011-06-28 2014-10-01 华博生物医药技术（上海）有限公司 新型重组双功能融合蛋白及其制法和用途
WO2013063536A1 (fr) * 2011-10-27 2013-05-02 Acceleron Pharma, Inc. AGENTS DE LIAISON À ActRIIB ET UTILISATIONS DE CEUX-CI
HUE034593T2 (en) 2012-03-28 2018-02-28 Univ Texas TGF II-III. types of receptor fusions
JP2016528295A (ja) 2013-08-22 2016-09-15 アクセルロン ファーマ， インコーポレイテッド Ｔｇｆ−ベータ受容体ｉｉ型変異体およびその使用
WO2016090035A2 (fr) 2014-12-02 2016-06-09 La Jolla Institute For Allergy And Immunology Modulateurs de l'activine et procédés de modulation de réponses immunitaires et de cellules t auxiliaires folliculaires
WO2016164089A2 (fr) 2015-04-06 2016-10-13 Acceleron Pharma Inc. Hétéromultimères de récepteur de type i et de type ii de la superfamille de tgf-bêta et leurs utilisations
RS61728B1 (sr) 2015-04-06 2021-05-31 Acceleron Pharma Inc Jednograni fuzioni receptorski proteini tipa i i tipa ii i njihove upotrebe
MA41919A (fr) 2015-04-06 2018-02-13 Acceleron Pharma Inc Hétéromultimères alk4:actriib et leurs utilisations
CA2983440C (fr) 2015-04-22 2024-03-12 Alivegen Usa Inc. Nouvelles proteines hybrides piegeant le ligand actriib pour le traitement de maladies amyotrophiques
WO2016205370A1 (fr) 2015-06-15 2016-12-22 Santa Maria Biotherapeutics, Inc. Méthodes d'utilisation de protéines à base du récepteur iib de l'activine
EP3344660A4 (fr) 2015-08-31 2019-07-03 National Research Council of Canada Molécules de fusion d'ectodomaines du récepteur du tgf-b et leurs utilisations
US20170306027A1 (en) 2016-04-06 2017-10-26 Acceleron Pharma Inc. Alk7 antagonists and uses thereof
JP7159148B2 (ja) 2016-07-07 2022-10-24 アクセルロン ファーマ インコーポレイテッド Ｔｇｆベータスーパーファミリーホモ多量体およびその使用
WO2018009732A1 (fr) 2016-07-08 2018-01-11 Regeneron Pharmaceuticals, Inc. Anticorps anti-activine a et méthodes d'utilisation de ces anticorps dans le traitement de l'hypertension artérielle pulmonaire
US10934532B2 (en) 2016-10-05 2021-03-02 Acceleron Pharma Inc. ALK4.ActRIIB heteromultimers
JOP20190085A1 (ar) 2016-10-20 2019-04-17 Biogen Ma Inc طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة

Also Published As

Publication number Publication date
MA53400A (fr) 2021-08-04
US20160297867A1 (en) 2016-10-13
EP3280728A1 (fr) 2018-02-14
HK1248735A1 (zh) 2018-10-19
HK1250373A1 (zh) 2018-12-14
AU2016246708A1 (en) 2017-10-26
JP7037363B2 (ja) 2022-03-16
AU2016244750B2 (en) 2021-02-18
BR112017021510A2 (pt) 2018-07-03
EP3280728B1 (fr) 2020-12-16
CN107847561B (zh) 2022-03-29
US20220119491A1 (en) 2022-04-21
EP3280435B1 (fr) 2021-06-02
HK1252957A1 (zh) 2019-06-06
WO2016164503A1 (fr) 2016-10-13
DK3280728T3 (da) 2021-03-01
CN107709358A (zh) 2018-02-16
EP3828199A1 (fr) 2021-06-02
US11827689B2 (en) 2023-11-28
US11028145B2 (en) 2021-06-08
AU2016244750A1 (en) 2017-10-26
WO2016164089A3 (fr) 2016-12-08
JP2018517399A (ja) 2018-07-05
CA2981833A1 (fr) 2016-10-13
US20190225669A1 (en) 2019-07-25
US20240158468A1 (en) 2024-05-16
CA2981737A1 (fr) 2016-10-13
EP3280728A4 (fr) 2018-09-12
US20160298093A1 (en) 2016-10-13
US10906958B2 (en) 2021-02-02
AU2021200492A1 (en) 2021-02-25
JP2021104057A (ja) 2021-07-26
EP3889171A1 (fr) 2021-10-06
ES2863564T3 (es) 2021-10-11
EA202190016A1 (ru) 2021-08-31
JP7055636B2 (ja) 2022-04-18
KR20180002661A (ko) 2018-01-08
US10227393B2 (en) 2019-03-12
CN115073610A (zh) 2022-09-20
AU2016246708B2 (en) 2020-12-24
EA201792222A1 (ru) 2018-04-30
US10227392B2 (en) 2019-03-12
MA41916A (fr) 2021-04-14
JP2018513147A (ja) 2018-05-24
MA41920B1 (fr) 2021-05-31
AU2020281136A1 (en) 2021-01-07
CN107847561A (zh) 2018-03-27
MX2017012846A (es) 2018-11-09
WO2016164089A2 (fr) 2016-10-13
EP3280435A2 (fr) 2018-02-14
EP3280435A4 (fr) 2018-12-19
HK1248733A1 (zh) 2018-10-19
KR20180002659A (ko) 2018-01-08
US20220396607A1 (en) 2022-12-15
US20190375820A1 (en) 2019-12-12
MA41920A (fr) 2018-02-14
JP7246618B2 (ja) 2023-03-28
EA037293B1 (ru) 2021-03-05
CN114736307A (zh) 2022-07-12

Similar Documents

Publication Publication Date Title
MA54328A (fr) Hétéromultimères de récepteur de type i et de type ii de la superfamille de tgf-bêta et leurs utilisations
MA56480A (fr) Agonistes du récepteur glp-1 et leurs utilisations
MA50256A (fr) Composés de pyrazolopyrimidinone et leurs utilisations
MA42622A (fr) Agents de liaison à tigit et leurs utilisations
MA49537A (fr) Anticorps anti-lag3 et leurs utilisations
MA50618A (fr) Polyrhérapies et leurs utilisations
MA41460A (fr) Agents de liaison à la tnfrsf et leurs utilisations
MA55044A (fr) Hétéromultimères alk4:actriib et leurs utilisations
DK3368572T3 (da) Anti-pd-1-antistoffer og -sammensætninger
ES2976108T3 (es) Sistemas y métodos de sensor de analito transcutáneo
MA43821A (fr) Pyrimidines et variantes de celles-ci, et leurs utilisations
MA43417A (fr) Agonistes améliorés du récepteur de l'apéline (apj) et leurs utilisations
MA46471A (fr) Protéines actriib à variant et leurs utilisations
DK3591944T3 (da) Anycast-baseret wide area-system til distribueret allokering og belastningsbalancering
MA46472A (fr) Hétéromultimères alk4:actriib et leurs utilisations
MA53883A (fr) Protéines de fusion de récepteur type i et type ii à bras unique et leurs utilisations
DK3368534T3 (da) Valbenazin-ditosylat og polymorfer deraf
MA44262A (fr) Bioconjugués et utilisations de ceux-ci
DK3308111T3 (da) Belastningsføler og belastningsføler-anlæg
MA43567A (fr) Anticorps pacap et leurs utilisations
MA45233A (fr) Anticorps anti-gitr et leurs utilisations
MA44489A (fr) Pyrimidines et variants de celles-ci, et leurs utilisations
MA46945A (fr) Exopolysaccharides et leurs utilisations
EP3522912A4 (fr) Hétéromultimères de récepteurs de type i et de type ii de la superfamille des tgf-bêta et leurs utilisations
MA41495A (fr) Composés benzoxaborole et leurs utilisations